INDIVIDUAL PEPTIDE PROFILE
MK-677 (Ibutamoren)
MK-677, known as ibutamoren, is an orally active, non-peptide small molecule that mimics ghrelin, stimulating the pituitary gland to release growth hormone and raise IGF-1 levels. Because it is taken by mouth and does not need injection, it has attracted research and commercial interest as an alternative route to growth hormone axis stimulation, though it is not itself growth hormone or a peptide.
WHAT IT IS
MK-677 is a synthetic small molecule, chemically unrelated to peptide growth hormone secretagogues such as GHRP-2 or ipamorelin, even though it produces a similar downstream effect. It works by binding the ghrelin receptor (growth hormone secretagogue receptor, GHSR) in the pituitary and hypothalamus, prompting pulsatile release of the body's own growth hormone.
Unlike injectable growth hormone secretagogue peptides, MK-677 is orally bioavailable and has a long half-life, allowing once-daily dosing in the research settings where it has been studied. It was originally developed by Merck for potential use in growth hormone deficiency, sarcopenia and frailty in older adults, but it was never brought to market.
FDA status: MK-677 has not been approved by the FDA for any indication and is not a legal dietary supplement ingredient; it is sold online as a research chemical, and its identity, purity and dosing accuracy in such products cannot be verified.
WHAT RESEARCHERS STUDIED IT FOR
Clinical research on MK-677 has examined:
- Body composition and growth hormone/IGF-1 axis effects in healthy older adults
- Sleep quality, given ghrelin receptor activity's link to slow-wave sleep
- Functional recovery and lean mass preservation in frail older adults recovering from hip fracture surgery
- Reversal of diet-induced catabolism and preservation of lean mass during caloric restriction
PROPOSED BIOLOGICAL MECHANISMS
MK-677 activates the ghrelin receptor, which stimulates the pituitary to release growth hormone in a pulsatile pattern similar to natural secretion, subsequently raising circulating IGF-1. Ghrelin receptor activation is also linked to appetite stimulation and effects on sleep architecture.
Because it acts upstream of growth hormone itself, rather than supplying the hormone directly, its effects depend on a functioning pituitary and are generally less pronounced and more variable than direct growth hormone administration.
Chronic elevation of growth hormone and IGF-1 through this pathway can also affect insulin sensitivity and fluid balance, mechanisms shared with growth hormone itself.
AREAS OF RESEARCH INTEREST
- Whether the cardiovascular safety signal seen in the hip-fracture trial reflects a class effect, a population-specific risk in frail older adults, or a chance finding
- Whether MK-677's effects on lean mass and appetite have any role in defined clinical populations such as cancer cachexia
- How MK-677's oral route and long half-life compare with injectable peptide secretagogues in terms of overall risk-benefit
- Long-term metabolic effects, including insulin resistance, with sustained use
WHAT THE EVIDENCE CURRENTLY SUGGESTS
In a randomized, placebo-controlled trial in healthy older adults (Nass et al., Annals of Internal Medicine 2008), MK-677 increased growth hormone and IGF-1 levels and modestly increased fat-free mass over two years, but did not improve measures of physical function or strength, and was associated with increased fasting glucose, increased insulin levels reflecting insulin resistance, and higher rates of fluid retention, joint pain and fatigue compared with placebo.
A separate randomized trial in frail older adults recovering from hip fracture surgery was stopped after an interim analysis found a higher rate of congestive heart failure and death in the MK-677 group compared with placebo, a safety signal serious enough to end that trial.
Taken together, the available controlled human trial data show measurable growth hormone axis stimulation without clear functional benefit in older adults, alongside metabolic and, in a vulnerable population, cardiovascular safety concerns.
A cardiovascular signal in a vulnerable population
WHY THE HIP-FRACTURE TRIAL FINDING MATTERS
The MK-677 hip-fracture recovery trial was halted after an interim safety review found more cases of congestive heart failure and death among participants receiving MK-677 than those on placebo.
This finding was specific to a frail, older post-surgical population, and it is not established that the same risk applies equally to younger or healthier users, but it is a documented, serious adverse outcome that ended a clinical trial and should not be minimized.
It also illustrates a pattern seen elsewhere in growth hormone axis research, where fluid retention and cardiac strain are recognized mechanisms of concern with sustained growth hormone or IGF-1 elevation, particularly in people with underlying cardiovascular vulnerability.
Research Reality Check
What we know
MK-677 is an oral, non-peptide small molecule that stimulates growth hormone and IGF-1 release via the ghrelin receptor. In healthy older adults, a two-year randomized trial found modest fat-free mass increases without functional improvement, alongside increased fasting glucose, insulin resistance markers, fluid retention and joint pain. A separate trial in frail older adults recovering from hip fracture was stopped early after MK-677 was associated with more congestive heart failure and death than placebo.
What remains uncertain
Whether the cardiovascular safety signal from the hip-fracture trial generalizes to healthier or younger populations, and whether any specific clinical population would have a favorable risk-benefit profile with MK-677 given the documented metabolic and cardiac findings.
Educational commentary, not personal testimonial
The Balanced Body Lifestyle Take
MK-677 gets grouped with peptides constantly because of what it does, but it is not a peptide, and that distinction matters when you are weighing evidence. The oral convenience is real, but the hip-fracture trial finding on heart failure is one of the more sobering safety signals in this entire field, and it deserves to be taken seriously rather than glossed over.
If MK-677 has caught your attention, reach out to us. We can talk through what drew you to it, answer your questions honestly, and look at what current research does and does not show.
QUESTIONS PEOPLE OFTEN ASK
SOURCES & FURTHER READING
- PubMed: Nass R et al., Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults, a randomized, controlled trial (Ann Intern Med 2008)
- PubMed: Murphy MG et al., MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (J Clin Endocrinol Metab)
- ClinicalTrials.gov: Study of MK-677 (Ibutamoren) in patients following hip fracture surgery
- PubMed: Adunsky A et al., Blocked randomized trial of MK-0677 for functional recovery after hip fracture surgery
Peptide Education Consultation
Interested in learning more about peptides? Schedule an educational consultation with Vince Angelo to discuss the information and ask questions.
Schedule an Educational ConsultationEDUCATIONAL NOTICE
The Balanced Body Lifestyle™ provides peptide and wellness information for educational purposes only. Content is intended to help readers better understand emerging research, established evidence and areas of scientific uncertainty. It is not medical advice, diagnosis, treatment guidance or a recommendation to use any medication, peptide or research compound. Decisions involving prescription medications or investigational compounds should be discussed with a qualified healthcare professional.
THE BALANCED BODY LIFESTYLE
A healthy life is built on balance.